ArticlePloS one2025
Optimizing CMV therapy: Population pharmacokinetics and Monte Carlo simulations for letermovir and maribavir dosage.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study seeks to reassess and enhance the dosing strategies of letermovir and maribavir for treating cytomegalovirus (CMV) infection, aiming to propose adjustments that could improve therapeutic effectiveness.
methodsPre-existing population pharmacokinetic models were used alongside Monte Carlo simulations to evaluate the dosing strategies of letermovir and maribavir in CMV treatment. The simulations assessed the probability of target attainment for current and alternative dosing regimens, including scenarios with missed doses.
resultsFor letermovir, a loading dose on the first day of treatment initiation appeared more effective than the current strategy without a loading dose. Additionally, in cases of missed doses, doubling the dose upon resumption was more effective than returning to the normal dosage. For maribavir, the current 400mg BID regimen only covers the lower end of the inhibitory concentration 50 range, suggesting a potential benefit from increasing the doses. Simulations indicated that for missed doses, all tested regimens only covered the lower range of inhibitory concentrations, but the current strategy of resuming the normal dosage provided the lowest chances of target attainment.
conclusionOur findings suggest a strong rationale to reconsider and potentially modify the approved dosing guidelines for letermovir and maribavir in CMV treatment. Adjusting dosing regimens, including the use of loading doses and increased doses after missed doses, could enhance treatment outcomes by ensuring higher probabilities of achieving therapeutic targets and better managing missed doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.